{"title":"在CDK4/6抑制剂（BYLieve）治疗pik3ca突变、激素受体阳性的晚期乳腺癌后，alpelisib + fulvestrant治疗的撤回和重建：一项2期、多中心、开放标签、非比较研究","authors":"","doi":"10.1016/s1470-2045(24)00647-8","DOIUrl":null,"url":null,"abstract":"In April, 2021, <em>The Lancet Oncology</em> published results of the phase 2 BYLieve study on alpelisib plus fulvestrant in <em>PIK3CA</em>-mutated, hormone receptor-positive advanced breast cancer.<span><span><sup>1</sup></span></span>","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study\",\"authors\":\"\",\"doi\":\"10.1016/s1470-2045(24)00647-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In April, 2021, <em>The Lancet Oncology</em> published results of the phase 2 BYLieve study on alpelisib plus fulvestrant in <em>PIK3CA</em>-mutated, hormone receptor-positive advanced breast cancer.<span><span><sup>1</sup></span></span>\",\"PeriodicalId\":22865,\"journal\":{\"name\":\"The Lancet Oncology\",\"volume\":\"26 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s1470-2045(24)00647-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s1470-2045(24)00647-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Retraction and republication—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
In April, 2021, The Lancet Oncology published results of the phase 2 BYLieve study on alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer.1
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
